Research programme: cannabinoid-based liver therapeutics - Revive Therapeutics/Sanyal Biotechnology

Drug Profile

Research programme: cannabinoid-based liver therapeutics - Revive Therapeutics/Sanyal Biotechnology

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Revive Therapeutics; Sanyal Biotechnology
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor CB1 modulators; Cannabinoid receptor CB2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Liver disorders

Most Recent Events

  • 02 Oct 2017 Revive Therapeutics and Sanyal Biotechnology agree to co-develop cannabinoid-based therapeutics for Liver disorders
  • 02 Oct 2017 Early research in Liver disorders in Canada (unspecified route)
  • 02 Oct 2017 Early research in Liver disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top